Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals — Investor Presentation (October 2020)

26 slides from Bellicum Pharmaceuticals's investor presentation, Oct 29, 2020

  1. Slide 1: Building a powerful new future in cellular IO

    Investor Presentation Building a powerful new future in cellular IO October 2020 Exhibit 99.2

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ platform, and related technologies; our product candidates including BPX-601, BPX-603, and

  3. Slide 3: Building a Powerful New Future in Cellular IO

    Power Re-ignites the host immune response, unleashing the power to combat tumor tolerance and intensify tumor killing Proliferation Boosts effector cell proliferation and extends survival, potentially leading to more durable responses Persistence Enhances effector cell functional persistence by resi

  4. Slide 4: Product Pipeline

    Product Candidate Discovery IND-Enabling Clinical Proof-of-Concept BPX-601 PSCA GoCAR-T BPX-603 HER2 GoCAR-T (Dual-Switch) Product Pipeline Establishing the clinical value of GoCAR-T in solid tumors to propel cellular IO forward PSCA+ Pancreatic Cancer Prostate Cancer HER2+ Solid Tumors

  5. Slide 5: Technology Overview

    Technology Overview *2> Bellicum :

  6. Slide 6: GoCAR: Differentiated Technology Platform

    GoCAR: Differentiated Technology Platform Current Generation CAR Technology Next Generation GoCAR Technology Rimiducid Inducible MyD88/CD40 ”iMC”

  7. Slide 7: GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion

    GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion iMC activation limits T cell dysfunction in repeat tumor stimulation exhaustion assay Repeat tumor exposure T cell Functional assays HER2+ tumor cells BPX-603 + Rim BPX-603 + Rim

  8. Slide 8: GoCAR Persistence: Resistance to Immune Suppressive TME

    GoCAR Persistence: Resistance to Immune Suppressive TME iMC overrides common inhibitory molecules in the tumor microenvironment PD-L1 TGF-b PGE2 M2 MF MDSC BPX-601 + Rim BPX-601 + Rim ↓ Inhibition ↓ Inhibition Inhibitory TME TME – tumor microenvironment

  9. Slide 9: BPX-601 PSCA GoCAR-T

    BPX.OQiil PSCA GoCAR-T

  10. Slide 10: BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA

    BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA High unmet need in solid tumors expressing prostate stem cell antigen (PSCA) Attractive first-in-class solid tumor CAR-T opportunity First-in-human experience with iMC Phase 1 pancreatic results to date demonstrate manageable safety, iMC-driven T

  11. Slide 11: BPX-601: Phase 1 Trial

    BPX-601: Phase 1 Trial Dose escalation in relapsed/refractory pancreatic cancer Lead-in (Cohort 0) Dose Escalation (Cohorts 3, 4, 5A) Standard Conditioning (Cohort 5B) Repeat Rimiducid (Cohort 5C) Pancreatic Patient Population 2L to 6L 2L to 6L 2L 2L BPX-601 Dose x106 cells/kg @ Day 0 1.25 1.25, 2.5

  12. Slide 12: BPX-601: Safety Reported Through Cohort 5C

    BPX-601: Safety Reported Through Cohort 5C Updated based on data cut July 9, 2020* Patients, n (%) Cohort 0 n = 3 Cohort 3 n = 3 Cohort 4 n = 3 Cohort 5A n = 4 Cohort 5B n = 5 Cohort 5C n=4 All Patients N = 22 Any AE 3 (100) 3 (100) 3 (100) 4 (100) 5 (100) 4 (100) 22 (100) Any SAE 2 (67) 1 (33) 0 3

  13. Slide 13: BPX-601: Updated Efficacy Through Cohort 5C

    *BPX-601 Investigator’s Brochure v4, 4 September 2020 BPX-601: Updated Efficacy Through Cohort 5C Updated based on data cut July 9, 2020* *BPX-601 Investigator’s Brochure v4, 4 September 2020 Patients, n (%) Cohort 0 n = 3 Cohort 3 n = 3 Cohort 4 n = 3 Cohort 5A n = 4 Cohort 5B n = 5 Cohort 5C n=4 O

  14. Slide 14: Interim Update: BPX-601 Cohort 5C

    Interim Update: BPX-601 Cohort 5C As of July 6, 2020, four patients treated with BPX-601 followed by 2-11 doses of rimiducid in cohort 5C Administration of BPX-601 and repeat doses of rimiducid was tolerated No treatment related adverse events ≥Grade 2 observed in these four patients; one treatment-

  15. Slide 15: BPX-601: GoCAR-T Increased Immunomodulatory Cytokines

    BPX-601: GoCAR-T Increased Immunomodulatory Cytokines Infusion of BPX-601 and activation with rimiducid increased immunomodulatory cytokines Increases in Th1 and Th2 cytokines were observed with: Administration of BPX-601 GoCAR-T cells GoCAR-T activation with rimiducid Stacked bars represent the sum

  16. Slide 16: BPX-601: GoCAR-T Infiltrated Metastatic Pancreatic Tumors

    BPX-601: GoCAR-T Infiltrated Metastatic Pancreatic Tumors On-treatment biopsies taken from metastatic lesions show BPX-601 tumor infiltration CD3 = Blue; BPX-601 = Red, arrows (Left) Stacked bars represent the total number of BPX-601 cells quantified in ISH stained tissue sections of available (n=3)

  17. Slide 17: BPX-601: Modulation of Tumor Microenvironment

    BPX-601: Modulation of Tumor Microenvironment Changes in gene expression consistent with productive T cell immune responses Differentially Expressed Genes in Tumor Metastases After BPX-601 + Rim (Cohort 5B, n=3) Effector T/ CAR-T Cell Associated Genes Upregulation of T/CAR-T cell associated genes in

  18. Slide 18: BPX-603 HER-2 GoCAR-T

    BPX-603 HER-2 GoCAR-T

  19. Slide 19: BPX-603 Dual Switch GoCAR-T Targeting HER2

    BPX-603 Dual Switch GoCAR-T Targeting HER2 Indication Incidence1 HER2+ 5-year OS (Stage IV)1 Gastric 28,000 10-30%3 <20% Colorectal 145,000 10%4 <15% Ovarian 22,000 20-30%5 <30% Uterine/ Endometrial 61,000 50-80%6 14-69% Glioblastoma 12,000 20-30%2 <20% Breast 271,000 16%7 90% Unmet Need Product Pro

  20. Slide 20: Historical HER2 Studies: Modest Clinical Outcomes

    Historical HER2 Studies: Modest Clinical Outcomes Study Properties Morgan, 2010 Ahmed, 2015 Feng, 2017 Ahmed, 2017 Hegde, 2019 Construct 4D5-28-BB-z FRP5-28-z Her2-BB-z FRP5-28-z FRP5-28-z Indication(s) Metastatic colon Sarcomas CCA and PCa GBM Sarcomas Patient number 1 19 11 17 10 HER2 expression ≥

  21. Slide 21: BPX-603: Compelling Preclinical Evidence

    BPX-603: Compelling Preclinical Evidence iMC co-activation enhances cell proliferation relative to current CAR-T standards BPX-603 + Rim BPX-603 + Rim Moderate affinity scFv enhances anti-tumor effect relative to low affinity FRP5

  22. Slide 22: BPX-603 Phase 1/2 Trial Design

    BPX-603 Phase 1/2 Trial Design Two-Part Safety/Activity Study of HER2-Targeted Dual Switch GoCAR-T Cells in Previously Treated HER2+ Solid Tumors Locally advanced or metastatic HER2+ solid tumors1 where standard treatment is no longer effective, does not exist, or subject is ineligible2 Escalating d

  23. Slide 23: Summary

    Summary

  24. Slide 24: Near-Term Restructuring Plan

    Near-Term Restructuring Plan Focus on clinical development of BPX-601 and BPX-603 Pause BCMA GoCAR-NK program and discontinue discovery research and new product development Reduce headcount by 81%, from 68 to 13 full-time employees during Q4 2020, with estimated severance costs of ~$2 million Settle

  25. Slide 25: Anticipated Key Program Goals & Milestones

    Goals & Milestones Planned Timing Phase 1 data update – mCRPC & Pancreatic Phase 1 data update - mCRPC 2H’21 2022 Initiate Phase 1/2 trial Initial Phase 1 data Phase 1 data update Q4’20 2H’21 2022 Anticipated Key Program Goals & Milestones BPX-601 BPX-603

  26. Slide 26: Investment Summary

    Investment Summary Building a next generation cell therapy pipeline around the GoCAR platform GoCAR Platform Differentiated co-activation domain (MyD88/CD40) and switch technology drive greater proliferation, persistence, power, and performance Cash runway extends into 2H’21 $54.6M total cash and $2

Bellicum Pharmaceuticals — Investor Presentation (October 2020) on 6ix